MedTrace Logo

A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism

NCT03108833 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2021-03-18

No results posted yet for this study

Summary

This trial is being conducted to assess the efficacy and safety of recombinant Human Prourokinase in the acute pulmonary embolism.

Conditions

  • Acute Pulmonary Embolism

Interventions

DRUG

Recombinant Human Prourokinase

The drug is used for intravenous thrombolysis therapy

DRUG

Alteplase

The drug is used for intravenous thrombolysis therapy

Sponsors & Collaborators

  • Tasly Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-06
Primary Completion
2019-12-19
Completion
2019-12-19

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03108833 on ClinicalTrials.gov